Rocket Pharmaceuticals (RCKT) Accounts Payables (2014 - 2026)

Rocket Pharmaceuticals (RCKT) has 13 years of Accounts Payables data on file, last reported at $21.5 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 33.58% year-over-year to $21.5 million; the trailing twelve-month figure through Mar 2026 stood at $21.5 million (down 33.58% YoY), and the FY2025 full-year result was $27.3 million, down 27.85% from the prior year.
• Accounts Payables slipped to $21.5 million in Q1 2026, from $27.3 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $45.8 million in Q4 2023 to a low of $20.0 million in Q1 2022.
• A 5-year average of $31.3 million and a median of $30.6 million in 2023 frame the typical range for Accounts Payables.
• Peak annual rise in Accounts Payables reached 86.9% in 2022, while the deepest fall reached 39.61% in 2022.
• Tracing RCKT's Accounts Payables over 5 years: stood at $36.7 million in 2022, then increased by 24.9% to $45.8 million in 2023, then fell by 17.39% to $37.8 million in 2024, then slipped by 27.85% to $27.3 million in 2025, then dropped by 21.07% to $21.5 million in 2026.
• Business Quant data shows RCKT's Accounts Payables at $21.5 million in Q1 2026, $27.3 million in Q4 2025, and $28.3 million in Q3 2025.